Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: immune modulation therapy - Celldex Therapeutics

Drug Profile

Research programme: immune modulation therapy - Celldex Therapeutics

Alternative Names: LOR-A04; LOR-S01; LOR-S03

Latest Information Update: 27 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lorantis
  • Developer Celldex Therapeutics Inc; Lorantis
  • Class Bispecific antibodies; DNA; Proteins
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Allergic asthma; Immunological disorders; Multiple sclerosis; Rheumatoid arthritis; Transplant rejection; Viral infections

Most Recent Events

  • 21 Apr 2018 Preclinical trials in Cancer in United Kingdom (unspecified route)
  • 21 Apr 2018 Pharmacodynamics data from a preclinical trial in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 12 Oct 2005 Lorantis has been acquired by Celldex Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top